Platinum-doublet chemotherapy was historically the standard first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors lack of epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.